Parexel Lowers Guidance On Restructuring, Stock Falls
Clinical research organization Parexel International (PRXL) plunged more than 7% Wednesday, off record highs, after it lowered its guidance late Tuesday ahead of its investor day. Parexel said it now expects revenue for the fiscal Q4 ending June 30 to be $517 million to $533 million, down from its previous guidance of $520 million to $540 million. Earnings will be taking a hit in the range of $20 to $30 million, lowering GAAP EPS guidance by about